Balyasny Asset Management

Balyasny Asset Management’s enGene Therapeutics ENGN Stock Holding History

Balyasny Asset Management’s Portfolio ENGN Stock Details ENGN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$7.82M	Buy	+1,148,997	New	+$10.2M	0.01%	1147

Other funds holding ENGN

FCPM III Services Naarden, Netherlands $722M AUM 73.61% 1-Year Est. Return

Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return

Siren LLC Greenwich, Connecticut $3.61B AUM 203.3% 1-Year Est. Return

VR Adviser New York $2.68B AUM 422.73% 1-Year Est. Return

Blue Owl Capital Holdings New York $372M AUM 78.25% 1-Year Est. Return

Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return

Braidwell Stamford, Connecticut $3B AUM 46.72% 1-Year Est. Return

Nextech Invest Zurich, Switzerland $1.42B AUM 304.47% 1-Year Est. Return

Vestal Point Capital New York $3.58B AUM 189.12% 1-Year Est. Return

MPM BioImpact Boston, Massachusetts $1.29B AUM 141.72% 1-Year Est. Return

Balyasny Asset Management's ENGN Position: Q1 2026 in Review

Balyasny Asset Management opened a new position in enGene Therapeutics (ENGN) in Q1 2026: 1,148,997 shares worth $7.82M. The stake represents 0.01% of the portfolio and ranks #1147 among its holdings.

61 funds tracked by Wall St. Rank hold ENGN as of Q1 2026.

Balyasny Asset Management held 1,148,997 shares of enGene Therapeutics worth $7.82M as of Q1 2026.
enGene Therapeutics was a new Balyasny Asset Management position in Q1 2026.
enGene Therapeutics made up 0.01% of Balyasny Asset Management's portfolio in Q1 2026, its #1147 holding.
61 funds tracked by Wall St. Rank held enGene Therapeutics as of Q1 2026.

Based on Balyasny Asset Management's 13F filing for Q1 2026, filed 15 May 2026.